Terms: = Ovarian cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
25 results:
1. CD133, CD47, and pd-l1 Expression in ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract] [Full Text] [Related]
2. Expression of EGFR, pd-l1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
3. Necroptosis-related regulatory pattern and scoring system for predicting therapeutic efficacy and prognosis in ovarian cancer.
Lai H; Guo Y; Wu L; Yusufu A; Zhong Q; Liao Z; Ma J; Shi W; Yang G; Chen S
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1893. PubMed ID: 37681751
[TBL] [Abstract] [Full Text] [Related]
4. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
5. Low plasma pd-l1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
6. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
7. Targeting PD-1/pd-l1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract] [Full Text] [Related]
8. Biomarkers of Central Nervous System Involvement from Epithelial ovarian cancer.
Scotto G; Borella F; Turinetto M; Tuninetti V; Valsecchi AA; Giannone G; Cosma S; Benedetto C; Valabrega G
Cells; 2021 Dec; 10(12):. PubMed ID: 34943916
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors.
Buza N
Semin Diagn Pathol; 2022 Jan; 39(1):58-77. PubMed ID: 34750021
[TBL] [Abstract] [Full Text] [Related]
11. Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer.
Nero C; Romito I; Spadola S; Romito A; Turco LC; Cosentino F; De Ninno M; Catena U; De Cicco Nardone A; Moroni R; Zannoni G; Fagotti A; Scambia G
Fertil Steril; 2022 Jan; 117(1):160-168. PubMed ID: 34656305
[TBL] [Abstract] [Full Text] [Related]
12. ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
Lai J; Tong C; Chien JR
Anticancer Res; 2021 Sep; 41(9):4417-4422. PubMed ID: 34475063
[TBL] [Abstract] [Full Text] [Related]
13. Primary ovarian Melanoma Arising From a Mature Teratoma With Melanoma In Situ Present in the Ciliated Columnar and Squamous Epithelium in a Patient With Synchronous Skin Basal Cell Carcinoma.
Lai J; Garvey KY; Li P; Azevedo RA
Int J Gynecol Pathol; 2021 Jul; 40(4):383-390. PubMed ID: 33560745
[TBL] [Abstract] [Full Text] [Related]
14. Potential Novel ovarian cancer Treatment Targeting Myeloid-Derived Suppressor Cells.
Abiko K; Hayashi T; Yamaguchi K; Mandai M; Konishi I
Cancer Invest; 2021 Apr; 39(4):310-314. PubMed ID: 33428503
[TBL] [Abstract] [Full Text] [Related]
15. Diffuse Intratumoral Stromal Inflammation in ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High pd-l1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract] [Full Text] [Related]
16. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract] [Full Text] [Related]
17. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma.
Horn LC; Höhn AK; Krücken I; Stiller M; Obeck U; Brambs CE
J Cancer Res Clin Oncol; 2020 Apr; 146(4):971-983. PubMed ID: 31927619
[TBL] [Abstract] [Full Text] [Related]
18. [Characterization of chosen pro-angiogenic factors and anti-angiogenic therapies in ovarian cancer].
Wiśniewski K; Pawłowska A; Bobiński M; Okła K; Kotarski J; Wertel I
Wiad Lek; 2018; 71(8):1603-1607. PubMed ID: 30684347
[TBL] [Abstract] [Full Text] [Related]
19. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract] [Full Text] [Related]
20. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract] [Full Text] [Related]
[Next]